Report from Orexo´s extraordinary general meeting

Rhea-AI Summary

Orexo AB announces election of new board member and dismissal of current member at extraordinary general meeting. Remuneration to the board of directors to continue as previously resolved. Complete proposals available on Orexo's website.

Positive

• Election of new board member Robin Evers
• Remuneration to board members to continue as previously resolved

Negative

• Dismissal of board member Henrik Kjær Hansen

STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- Election of new member of the board of directors

The extraordinary general meeting in Orexo AB (publ) on 26 October 2023 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members. Robin Evers was elected as a new board member. Furthermore, the board member Henrik Kjær Hansen was dismissed, as he had announced that he would resign from the board of directors in connection with the extraordinary general meeting.

Remuneration to the board of directors

The extraordinary general meeting also resolved, in accordance with the nomination committee's proposal, that the remuneration to the members of the board of directors and the committees resolved at the annual general meeting on 18 April 2023 shall continue to apply and shall, if applicable, be distributed pro rata to the chairman and the ordinary members of the board of directors, respectively, elected by each general meeting. Robin Evers shall not receive the additional board fee for acquisition of shares in Orexo.

Complete proposals regarding the resolutions by the extraordinary general meeting in accordance with the above are available at Orexo's website, www.orexo.com.

For further information please contact:

Orexo AB (publ.)

Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126. Orexo is listed on the Nasdaq Stockholm Main Market (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X (former Twitter), LinkedIn, and YouTube.

The following files are available for download:

https://mb.cision.com/Main/694/3863710/2389254.pdf

Orexo_PR_Report from Orexos EGM 2023_Published Oct. 26 2023

 

 

View original content:https://www.prnewswire.com/news-releases/report-from-orexos-extraordinary-general-meeting-301968932.html

SOURCE Orexo

FAQ

Who was elected as a new board member?

Robin Evers was elected as a new board member.

What is the status of the remuneration to the board of directors?

The remuneration to the board of directors will continue as previously resolved.

Where can I find the complete proposals regarding the resolutions?

The complete proposals are available on Orexo's website.